UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1

项目总结 临床试验是MD安德森癌症中心(MDACC)使命的组成部分。在2016财年，我们关心 大约135,000名患者，并招募了近1,000名干预研究的9,000多名患者。 MDACC为原NCI合作小组和新的国家临床中心做出了重大贡献 试验网络(NCTN)，包括强大的试验登记、科学和行政领导以及指导 早期职业教师参加这些重要的国家试验。2014-2017财年，在MDACC，858名患者 都参加了NCTN Network Group临床试验，包括684名患者进行的治疗试验 平均每年有215名患者。我们机构对NCTN活动的集中协调 促进了多学科创新试验的开发和进行。这种参与导致了 通过各种NCTN领导角色提供服务的机会。我们的机构还资助有才华的 临床和翻译研究人员申请成为NCTN成员，为早期职业生涯提供指导 教职员工，并鼓励申请NCTN同行评审的赠款资金。这些活动有助于 为NCTN LAPS U10赠款的成功以及为实现我们的使命而努力 通过癌症治疗、研究和治疗方面的进步，在德克萨斯州、全国和全球消除癌症 教育。我们的目标将继续与新提出的NCTN圈UG1拨款。

PROJECT SUMMARY Clinical trials are an integral part of MD Anderson Cancer Center’s (MDACC) mission. In FY2016, we cared for approximately 135,000 patients and enrolled more than 9,000 patients on nearly 1,000 interventional studies. MDACC has made significant contributions to the former NCI cooperative groups and the new National Clinical Trial Network (NCTN), including robust trial enrollment, scientific and administrative leadership, and mentoring early career faculty to participate in these important national trials. For FY 2014-2017, at MDACC, 858 patients were enrolled in NCTN Network group clinical trials, including 684 patients in therapeutic treatment trials resulting in an average of > 215 patients per year. Centralized coordination of NCTN activities at our institution has facilitated the development and conduct of multidisciplinary, innovative trials. This participation has led to opportunities for service through various NCTN leadership roles. Our institution has also sponsored talented clinical and translational investigators to apply for NCTN membership, provided mentorship of early career faculty, and encouraged applications for NCTN peer-reviewed grant funding. These activities have contributed to the success of the NCTN LAPS U10 grant as well as working towards the fulfillment of our mission of eliminating cancer in Texas, nationally, and globally through advances in cancer treatment, research and education. Our goals will continue with the newly proposed NCTN LAPS UG1 grant.